Apnimed completed an initial public offering of 12 million shares priced at $16 per share in July 2026 and filed its quarterly 10-Q report for Q2 2026 in September 2026, disclosing key financial metrics including revenue, net income, and liquidity ratios.

• Apnimed priced its initial public offering of 12 million shares at $16 per share on July 31, 2026, marking its entry into the public markets [N1].
• The company filed its quarterly 10-Q report on September 8, 2026, disclosing $12.08 million in revenue and $125.9 million in net income for the quarter ended June 30, 2026, along with strong liquidity ratios including a current ratio of 5.19 and a cash ratio of 4.86 [S1].

The company shows strong liquidity and profitability metrics in its latest quarterly report, supported by a successful initial public offering, which may provide capital for growth initiatives.

Lack of detailed information on the company's sector, industry, and operational specifics limits visibility into its business risks and competitive positioning. The absence of detailed risk factor disclosures beyond the mention in the 10-Q filing constrains comprehensive risk assessment.

Information on Apnimed's competitive advantages or unique market positioning is not disclosed in the available data, limiting assessment of its moat.

• Limited Public Information: The company has not disclosed detailed sector, industry, or operational information, which limits understanding of its business model and market environment.
• Concentration Risk from IPO: Recent capital raised through the initial public offering may expose the company to market and investor sentiment risks related to its public market debut.
• Financial Reporting Risks: While the company reports strong liquidity and profitability, the sustainability of these metrics is not detailed, and risk factors are only generally referenced in the 10-Q filing.

• Apnimed, Inc. completed an initial public offering of 12 million shares priced at $16 per share as of July 31, 2026.
• As of June 30, 2026, Apnimed reported cash and cash equivalents of $172.8 million.
• Current assets as of June 30, 2026, were $184.8 million, with current liabilities of $35.6 million, resulting in a current ratio of 5.19 and a cash ratio of 4.86, indicating strong liquidity.
• Reported revenue for the quarter ending June 30, 2026, was $12.08 million.
• Net income for the same period was $125.9 million, as reported in the 10-Q filed on September 8, 2026.
• The company filed a 10-Q quarterly report on September 8, 2026, which includes risk factors disclosure.
• The market price as of September 8, 2026, was $29 per share.